Immunovia AB Stock London S.E.

Equities

0G8X

SE0006091997

Advanced Medical Equipment & Technology

Real-time Estimate Cboe Europe 10:27:11 2024-05-14 EDT 5-day change 1st Jan Change
1.56 SEK +11.43% Intraday chart for Immunovia AB 0.00% -22.82%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 1.14M 106K 144K Sales 2023 1.58M 146K 198K Capitalization 80.25M 7.41M 10.11M
Net income 2022 -168M -15.52M -21.17M Net income 2023 -309M -28.55M -38.94M EV / Sales 2022 460 x
Net cash position 2022 68.47M 6.33M 8.63M Net cash position 2023 72.5M 6.7M 9.14M EV / Sales 2023 4.92 x
P/E ratio 2022
-3.54 x
P/E ratio 2023
-0.22 x
Employees 11
Yield 2022 *
-
Yield 2023
-
Free-Float 75.11%
More Fundamentals * Assessed data
Dynamic Chart
1 day+11.43%
3 months-27.79%
6 months+41.56%
Current year-22.82%
More quotes
Current year
1.40
Extreme 1.4
2.26
1 year
0.99
Extreme 0.985
3.30
3 years
0.99
Extreme 0.985
139.14
5 years
0.99
Extreme 0.985
292.00
10 years
0.99
Extreme 0.985
292.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO 62 22-03-31
Chief Operating Officer 61 23-02-28
Members of the board TitleAgeSince
Director/Board Member 70 16-12-08
Chairman 67 19-12-31
Director/Board Member - 23-05-21
More insiders
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Calendar
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW